The goal is to make Israeli startups competitive in the U.S. Each early stage company in the program pays the government 3 percent to 5 percent of royalties from the revenue they generate until the full amount of the grant, including interest, is repaid, according to a website for the program. Teva and Philips’ Sanara Ventures has six companies in its portfolio such as home monitoring business spirCare and telehealth business My HomeDoc.Īs part of the program, incubators are given budgets ranging from $500,000 to $800,000 and 85 percent of that comes from the government through a grant - the rest is financed by the incubators. Johnson & Johnson opened a biotech accelerator with OrbiMed Israel and Takeda Pharmaceuticals called FutuRx and has built a portfolio of nine companies spanning pre-clinical treatments for cancer to Orphan diseases such as Wiskott-Aldrich syndrome and X-linked thrombocytopenia. The company develops an autonomous, continuous, non-invasive ultrasound device for patient monitoring, according to MindUp’s website. Although it was initially called Health 02, it launched last year as MindUp. The digital health incubator has one portfolio company to date - Hemonitor Medical. In 2015, Medtronic and IBM won a grant to set up a digital medicine incubator in Haifa with Pitango Venture Capital and Rambam Hospital. Israel’s incubator program has attracted several interesting collaborations. Haifa Digital Health, MindUP - the Digital Health Incubator, mHealth and BeWell.Haifa are exited to invite you to a truly inspirational event: celebrating the. It is designed to detect and count the insulin units injected and enable that information to be tracked by users. Insulog is developing a connected insulin pen cap for disposable insulin pens to support adherence. It can detect the chemical properties of the allergy-inducing compounds and alert users, according to a description of the company on the F6S website. Pending a due diligence review, it is considering a company focused on food allergies and another with a connected cap for insulin pens.ĪllerGuard is an early stage company that claims it is developing a matchbox-sized personal allergen hazard sensor to help people with strong food allergies. According to MindUP CEO Dan Shwarzman, one of Hemonitor's advantages is the possibility of working relatively early on a pilot with the Rambam Health Care Campus in order to verify that the product really meets the doctors' expectations.The Israeli digital health incubator also recently held a competition to select two more startups for its portfolio. The product won the Technion Biztech competition, after which it came into contact with the incubator. Hemonitor's product purports to be accurate enough to become a proper replacement for a catheter, while still costing less and being less invasive. Mayblum: "Our product will make it possible to expand the number of monitored patients and lower costs, compared with catheters." "From our understanding of the problem and a check we did at various departments in hospitals, it appears that these tests haven't really caught on." "There are a number of such companies, including Israeli ones, and these products are being used, mainly in Europe, but with rather limited success," he says. One example is technologies based on bio-impedance - the body's conductivity. Today, for example, when sepsis (an infection that causes a severe life-threatening immune reaction) is indicated, only 40% of patients are monitored in this way, and the proportion is even less for other indications."Īccording to Toume, attempts were made to replace the invasive catheter with less invasive technology, but all of them use indirect measurements they do not measure the blood flow in the main artery. This is usually done only for critical patients for whom the value of this test justifies its invasiveness, although every patient in intensive care really needs the test. Hemonitor cofounder and CTO Samer Toume explains, "Today, in order to obtain an accurate estimate of the blood flow, you have to put a catheter into the main artery. Using a smart algorithm, it is able to identify the blood flow parameters by itself." There is no need for the doctor or medical technician who looks for a special angle in a manual ultrasound. Hemonitor cofounder and CEO Tom Mayblum says, "Our device is small, and is attached as a patch below the side of the neck.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |